Trial Profile
Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 14 Nov 2018
Price :
$35
*
At a glance
- Drugs GC 3111 (Primary)
- Indications Diphtheria; Pertussis; Tetanus
- Focus Therapeutic Use
- 04 Nov 2016 Status changed from not yet recruiting to active, no longer recruiting.
- 08 Jul 2016 New trial record